Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 339 across all filing types
Latest filing 2025-02-14 Share Issue/Capital Cha…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Inify Laboratories - New share capital registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces that a 'New share capital [has been] registered' following a private placement and subsequent offering. It details the resulting increase in share capital and the total number of shares. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes.
2025-02-14 English
Inify Laboratories - New share capital registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces that the 'New share capital [has been] registered' following a previous resolution to issue new shares via a private placement and subsequent offering. It details the resulting new registered share capital (SEK 5,099,261 divided on 78,903,416 shares). This directly relates to a change in the company's capital structure due to the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general regulatory filing (RNS) because it is highly specific to a capital event, nor is it a financing update (CAP) which usually covers the *raising* of funds rather than the administrative registration of the resulting shares.
2025-02-14 English
Inify Laboratories – Resolution to issue new shares in Private Placement and Subsequent Offering
Share Issue/Capital Change Classification · 98% confidence The document explicitly details the resolution by the Board of Directors to issue new shares through a 'Private Placement' and a 'Subsequent Offering'. It discusses the allocation of these shares, registration with the Swedish Companies Registration Office, and advisor appointments related to these financing activities. This content directly relates to changes in the company's capital structure and fundraising efforts. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (3087 chars) is not indicative of a full report, but rather a specific announcement, which aligns with the CAP definition.
2025-02-12 English
Inify Laboratories - Resolution to issue new shares in Private Placement and Subsequent Offering
Share Issue/Capital Change Classification · 98% confidence The document explicitly details the resolution by the Board of Directors to issue new shares through a 'Private Placement' and a 'Subsequent Offering'. It discusses the allocation of these shares, registration with the Swedish Companies Registration Office, and advisor appointments related to these financing activities. This content directly relates to changes in the company's capital structure and fundraising efforts. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (3087 chars) is not indicative of a full report, but rather a specific announcement, which aligns with the CAP definition.
2025-02-12 English
Inify Laboratories - Resolution to issue new shares in Private Placement and Subsequent Offering
Capital/Financing Update Classification · 98% confidence The document explicitly details the resolution by the Board of Directors to issue new shares following a Private Placement and a Subsequent Offering. This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification, as it covers company fundraising and capital structure changes. The document is not a general regulatory filing (RNS) because it concerns a specific, major corporate finance event.
2025-02-12 English
Inify Laboratories - mandatory notification of trade
Director's Dealing Classification · 99% confidence The document is titled 'Inify Laboratories - mandatory notification of trade' and explicitly states that a primary insider (board member Olof Sandén) has acquired shares. It cites disclosure requirements under the EU Market Abuse Regulation (MAR) article 19, which specifically governs insider transactions. This directly corresponds to the definition of Director's Dealing (DIRS). The document is short and contains the transaction details, not just an announcement of a report.
2025-01-30 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.